Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Curis is engaged in the discovery of drug targets and development of therapeutics based on signaling pathways and stem cell technologies. The company recently announced a "Realignment" of its R&D programs to focus on proprietary signaling pathways (BMP and Hedgehog) and stem cell technologies, resulting in workforce reductions and the closure of certain clinical programs.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 |
Six Months Ended June 30, 2002 |
Six Months Ended June 30, 2001 |
|---|---|---|---|
| Total Revenues | $189,603 | $348,235 | $451,803 |
| Net Loss | $(70,993,187) | $(88,813,226) | $(37,084,237) |
| Net Loss Per Share (Basic/Diluted) | $(2.20) | $(2.76) | $(1.18) |
| Cash and Cash Equivalents (Total) | $30,630,344 (as of June 30, 2002) | ||
| Restricted Cash | $4,694,804 (as of June 30, 2002) | ||
| Marketable Securities | $12,389,278 (as of June 30, 2002) | ||
| Total Debt (Current + Long-Term) | $11,461,000 (as of June 30, 2002) | ||
| Net Cash Used in Operating Activities | $(14,413,967) (Six Months 2002) |
Material Changes vs. Prior Period
- Significant Non-Cash Charges: The net loss for the six months ended June 30, 2002, was heavily impacted by a $64,098,345 impairment charge on goodwill and a $5,336,785 impairment charge on property and equipment. These charges were driven by the adoption of SFAS No. 142 and the company's "Realignment" strategy.
- Realignment Expenses: The company recorded $3,490,000 in realignment expenses during the first half of 2002, related to workforce reductions (46 employees) and the decommissioning of a manufacturing facility.
- Revenue Decline: Total revenues decreased to $348,235 for the six months ended June 30, 2002, compared to $451,803 in the prior year period. This decline is attributed to the termination of two government grants in April 2002.
- Expense Reductions: Despite the impairment charges, ongoing operating costs decreased. Research and development expenses dropped 45% year-over-year, and stock-based compensation decreased significantly due to the vesting of merger-related options.
- Goodwill Accounting: The company ceased amortization of goodwill effective January 1, 2002, under SFAS No. 142, replacing it with an impairment test which resulted in the large write-down noted above.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management anticipates that existing capital resources, royalties from Stryker (OP-1), and borrowings under a Note Agreement with Elan Pharma International, Ltd. (EPIL) will fund operations into the fourth quarter of 2003.
- Future Funding Needs: Beyond late 2003, the company expects to incur substantial additional costs for preclinical studies and clinical trials. Continued funding depends on royalty generation, collaboration success, and the ability to raise additional equity or debt.
- Debt Obligations: On June 14, 2002, the company entered a $4.7 million loan with Boston Private Bank & Trust, collateralized by restricted cash. Additionally, the company has a convertible note agreement with EPIL to fund its 80.1% share of the Curis Newco joint venture expenses.
- Risks: Key risks include the failure to obtain regulatory approval for OP-1 beyond its current limited exemption, dependence on collaborative partners (Elan, Stryker), and the inability to raise additional capital on favorable terms. The company also faces foreign exchange risk on assets denominated in Euros.
Investor Verification Checklist
- Goodwill Impairment Methodology: Verify the assumptions used in the discounted cash flow analysis for the $64.1 million goodwill write-down, specifically the control premium and projected cash flows for in-process technology.
- Joint Venture Funding: Confirm the status of the Note Agreement with EPIL and the company's ability to draw down the remaining $5.4 million required to fund the Curis Newco joint venture through July 2003.
- Royalty Dependence: Assess the reliability of royalty revenue from Stryker regarding the OP-1 Implant, given the company's heavy reliance on this stream for future liquidity.
- Realignment Completion: Verify that the remaining $147,000 in realignment liabilities will be settled as projected and that no further restructuring costs are anticipated.
- Debt Covenants: Review the terms of the new $4.7 million loan with Boston Private Bank to ensure compliance with covenants and understand the impact of the variable interest rate.